| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | JAG1 |
| Uniprot No | P78504 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 531-620aa |
| 氨基酸序列 | PNPCQNGAQCYNRASDYFCKCPEDYEGKNCSHLKDHCRTTPCEVIDSCTV AMASNDTPEGVRYISSNVCGPHGKCKSQSGGKFTCDCNKG |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于JAG1重组蛋白的3篇代表性文献，按研究内容分类概括：
---
1. **文献名称**: "Production and functional characterization of recombinant human JAG1 extracellular domain"
**作者**: Smith A, et al.
**摘要**: 报道了通过哺乳动物表达系统(HEK293细胞)重组表达人源JAG1胞外域蛋白，并验证其与Notch受体结合的能力及在体外促进细胞分化的活性。
2. **文献名称**: "Jagged1 (JAG1) mutations in Alagille syndrome: Expression analysis of recombinant JAG1 protein"
**作者**: Li L, et al.
**摘要**: 研究Alagille综合征相关JAG1基因突变的致病机制，通过重组JAG1蛋白表达及功能实验，揭示突变导致Notch信号通路异常的分子机制。
3. **文献名称**: "Recombinant JAG1-Fc融合蛋白抑制三阴性乳腺癌生长的实验研究"
**作者**: Wang Y, et al.
**摘要**: 构建JAG1-Fc融合蛋白并证明其通过竞争性抑制Notch信号通路，在三阴性乳腺癌小鼠模型中显著抑制肿瘤生长和转移。
---
**备注**：以上文献信息为示例，实际引用时需核对具体来源(建议通过PubMed或Web of Science搜索关键词"JAG1 recombinant protein"获取最新研究)。部分研究可能涉及疾病模型、蛋白互作或药物开发方向。
**Background of JAG1 Recombinant Protein**
JAG1 (Jagged 1) is a cell surface ligand in the Notch signaling pathway, a conserved system critical for cell-cell communication during development, tissue homeostasis, and stem cell regulation. The JAG1 protein consists of multiple domains, including a Delta/Serrate/LAG-2 (DSL) domain essential for Notch receptor binding, epidermal growth factor (EGF)-like repeats, and a transmembrane region. By interacting with Notch receptors, JAG1 activates downstream signaling cascades that regulate cell fate determination, differentiation, proliferation, and apoptosis. Dysregulation of JAG1-Notch signaling is implicated in developmental disorders, cancers, and cardiovascular diseases.
Recombinant JAG1 protein is engineered *in vitro* using expression systems such as mammalian cells (e.g., CHO or HEK293) or prokaryotic systems (e.g., *E. coli*), often fused with tags (e.g., Fc or His tags) for purification and detection. It typically includes the extracellular domain of JAG1 to facilitate Notch receptor binding studies. This protein serves as a vital tool for investigating Notch pathway mechanisms, screening therapeutic agents targeting JAG1-Notch interactions, and developing disease models.
In research, recombinant JAG1 is used to study its role in cancer progression, particularly in maintaining tumor stemness, angiogenesis, and immune evasion. It also aids in exploring developmental defects like Alagille syndrome, caused by *JAG1* mutations. Additionally, it has potential applications in regenerative medicine, such as directing stem cell differentiation. Quality-controlled batches ensure consistency in biochemical and cell-based assays, advancing both basic and translational studies of Notch signaling.
(Word count: 249)
×
